
AntÃ³nio E Pinto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8441980/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort. Molecular and Clinical Oncology, 2019, 10, 644-654.	0.4	13
2	Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon. Oncology Letters, 2017, 13, 2027-2033.	0.8	9
3	Identification of somatic <i><scp>TERT</scp></i> promoter mutations in familial nonmedullary thyroid carcinomas. Clinical Endocrinology, 2017, 87, 394-399.	1.2	23
4	Aneuploidy identifies subsets of patients with poor clinical outcome inÂgrade 1 and grade 2 breast cancer. Breast, 2015, 24, 449-455.	0.9	13
5	Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. European Journal of Endocrinology, 2014, 170, 321-327.	1.9	40
6	Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 185-191.	1.4	18
7	Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer. SpringerPlus, 2013, 2, 375.	1.2	6
8	DNA Ploidy is an Independent Predictor of Survival in Breast Invasive Ductal Carcinoma: A Long-term Multivariate Analysis of 393 Patients. Annals of Surgical Oncology, 2013, 20, 1530-1537.	0.7	26
9	<scp>S</scp> â€phase fraction and ploidy as predictive markers in primary disease and recurrence of papillary thyroid carcinoma. Clinical Endocrinology, 2012, 77, 302-309.	1.2	4
10	High Prevalence of <i>RAS</i> Mutations in <i>RET</i> -Negative Sporadic Medullary Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E863-E868.	1.8	204
11	Ploidy and S-phase fraction as predictive markers of response to radiotherapy in cervical cancer. Pathology Research and Practice, 2011, 207, 623-627.	1.0	8
12	Underexpression of PPAR ^{î3} is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. Oncology Reports, 2009, 22, 907-13.	1.2	5
13	BCL-6 Oncoprotein in Breast Cancer: Loss of Expression in Disease Progression. Pathobiology, 2009, 76, 235-242.	1.9	14
14	Clinical implications of molecular markers in follicular cell-derived thyroid cancer. Expert Review of Molecular Diagnostics, 2009, 9, 679-694.	1.5	4
15	Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma. Oncology Reports, 2008, 20, 913-9.	1.2	11
16	Male and Female Breast Cancer – Differences in DNA Ploidy, p21 and p53 Expression Reinforce the Possibility of Distinct Pathways of Oncogenesis. Pathobiology, 2007, 74, 323-327.	1.9	23
17	Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncology Reports, 2007, , .	1.2	18
18	Aneuploidy and <i>RAS</i> mutations are mutually exclusive events in the development of wellâ€differentiated thyroid follicular tumours. Clinical Endocrinology, 2007, 67, 706-711.	1.2	17

ΑντÃ³νιο Ε Ρίντο

#	Article	IF	CITATIONS
19	Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncology Reports, 2007, 18, 917-26.	1.2	36
20	DNA Flow Cytometry but Not Telomerase Activity as Predictor of Disease-Free Survival in pT1–2/N0/G2 Breast Cancer. Pathobiology, 2006, 73, 63-70.	1.9	7
21	Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology, 2005, 37, 45-50.	0.3	32
22	Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma. Diagnostic Cytopathology, 2003, 29, 194-199.	0.5	12
23	Chromosome imbalances in thyroid follicular neoplasms: A comparison between follicular adenomas and carcinomas. Genes Chromosomes and Cancer, 2003, 36, 292-302.	1.5	62
24	Male Breast Cancer—A Reappraisal of Clinical and Biologic Indicators of Prognosis. Acta Oncológica, 2001, 40, 472-478.	0.8	24
25	Global DNA hypomethylation in breast carcinoma. , 1999, 85, 112-118.		157
26	The clinical relevance of ploidy and S-phase fraction determination in salivary gland tumors: A flow cytometric study of 97 cases. , 1999, 85, 273-281.		14
27	Follicular thyroid carcinoma: Chromosome analysis of 19 cases. , 1998, 21, 250-255.		34
28	Analysis of p53 expression in osteosarcoma of the jaw: Correlation with clinicopathologic and DNA ploidy findings. Human Pathology, 1997, 28, 1361-1365.	1.1	16
29	Flow cytometric DNA ploidy and S-phase fraction correlate with histopathologic indicators of tumor behavior in colorectal carcinoma. Diseases of the Colon and Rectum, 1997, 40, 411-419.	0.7	18
30	p53 protein immunoexpression in esophageal squamous cell carcinoma and adjacent epithelium. , 1997, 65, 3-9.		12
31	DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. , 1996, 78, 2300-2306.		54